No profile data available.
Outlook Therapeutics, Inc. (OTLK) is a healthcare company in the eye treatment pharmaceuticals industry, based in Iselin, United States, with about 17 full-time employees.
It reported revenue of $1.41 million for fiscal year 2025, and net income of -$62.42 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $8,700, down 99.4% from a year before. Its market capitalization was $145.80 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Outlook Therapeutics reported $1.41 million in revenue for fiscal year 2025. In Q3 2026 revenue was $8,700.
$145.80 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include EyePoint Pharmaceuticals, Inc. (EYPT), Lineage Cell Therapeutics, Inc. (LCTX), Opus Genetics, Inc. (IRD), Lenz Therapeutics, Inc. (LENZ).